ThermoGenesis says AXP system efficiently separates stem cells from cord blood

By Elaine Rigoli

Tampa, Fla., May 8 - ThermoGenesis Corp. announced that new performance data related to the company's AutoXpress system (AXP), designed to bring automation and precision to cord blood stem cell processing, can harvest 97% of the mononuclear cell population from cord blood consistently and efficiently.

When these cell populations are frozen and archived in the BioArchive system, the cell viabilities exceed 94% after thawing, according to a news release.

"Cord blood processing labs must use efficient and reliable methods for processing, cryopreserving, freezing and storing cord blood to maximize recovery and viability of hematopoietic stem and progenitor cells for bone marrow transplantation. These cells are critical to patients who require stem-cell reconstitution in the treatment of diseases like acute leukemia, lymphoma and numerous genetic diseases," said John Chapman, vice president of scientific affairs, in the release.

In October, GE Healthcare acquired the exclusive global distribution rights for the AXP from ThermoGenesis, as well as non-excusive distribution rights for the BioArchive system.

The company said it estimates that about 200 cord blood banks are operating in 44 countries and processing several hundred thousand cord-blood units annually.

Located in Rancho Cordova, Calif., ThermoGenesis develops and manufactures automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.